The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
A. X. Zhu
Consultant or Advisory Role - Novartis; Pfizer; Sanofi
Research Funding - Bayer
P. J. Gold
No relevant relationships to disclose
A. B. El-Khoueiry
Honoraria - AstraZeneca
Research Funding - Abraxis BioScience; AstraZeneca
T. A. Abrams
No relevant relationships to disclose
H. Morikawa
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
T. Ohtomo
Employment or Leadership Position - Chugai Pharma
P. A. Philip
Honoraria - Amgen; Bayer; Sanofi
Research Funding - Chugai Pharma; Lilly; Novartis